BIO-TECHNE Corp
TECH · XNASCIK 842023fmd_0CXEXY47HEC8N9KGM2YW2JWY7TManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2008 to Sep 30, 2026, 70 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 563 | 643 | 714 | 739 | 931 | 1,106 | 1,137 | 1,159 | 1,220 | 1,215 |
| Cost of revenue | 188 | 211 | 241 | 255 | 298 | 349 | 367 | 389 | 429 | 416 |
| Gross profit | 375 | 432 | 473 | 483 | 633 | 756 | 770 | 770 | 790 | 799 |
| Realized investment gains (losses) | – | – | – | – | (68) | 15 | 49 | 0 | – | (6) |
| Research and development | 54 | 55 | 62 | 65 | 71 | 87 | 92 | 97 | 99 | 95 |
| Selling, general and administrative | 200 | 241 | 264 | 261 | 325 | 373 | 378 | 466 | 589 | 452 |
| Total operating expenses | 254 | 296 | 327 | 326 | 396 | 460 | 471 | 563 | 688 | 547 |
| Operating income | 121 | 136 | 147 | 157 | 237 | 297 | 299 | 207 | 102 | 252 |
| Interest expense | 7 | 10 | 22 | 19 | 14 | 11 | 11 | 16 | 9 | 10 |
| Interest and investment income | – | – | – | – | – | – | 3 | 3 | 4 | 4 |
| Other non-operating income (expense) | (9) | (10) | (35) | 119 | (89) | 5 | 40 | (21) | (4) | (11) |
| Income before taxes | 112 | 126 | 112 | 276 | 148 | 301 | 339 | 186 | 98 | 241 |
| Income tax expense | 36 | (0) | 16 | 47 | 9 | 38 | 53 | 18 | 25 | 59 |
| Net income from continuing operations | 76 | 126 | 96 | 229 | 140 | 263 | 285 | 168 | 73 | 182 |
| Net income | 76 | 126 | 96 | 229 | 140 | 272 | 285 | 168 | 73 | 182 |
| Net income to common shareholders | 76 | 126 | 96 | 229 | 140 | 272 | 285 | 168 | 73 | 182 |